135 related articles for article (PubMed ID: 8747519)
1. Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin.
Qi R; Ozaki Y; Satoh K; Kurota K; Asazuma N; Yatomi Y; Kume S
Thromb Res; 1996 Jan; 81(1):43-54. PubMed ID: 8747519
[TBL] [Abstract][Full Text] [Related]
2. The effect of MCI-9042 on serotonin-induced platelet aggregation in type 2 diabetes mellitus.
Pietraszek MH; Takada Y; Taminato A; Yoshimi T; Watanabe I; Takada A
Thromb Res; 1993 Apr; 70(2):131-8. PubMed ID: 8322284
[TBL] [Abstract][Full Text] [Related]
3. Role of 5-hydroxytryptamine in platelet thrombus formation and mechanisms of inhibition of thrombus formation by 5-hydroxytryptamine2A antagonists in rabbits.
Takano S
Arch Int Pharmacodyn Ther; 1995; 330(3):297-308. PubMed ID: 8836449
[TBL] [Abstract][Full Text] [Related]
4. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
Ogawa T; Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
[TBL] [Abstract][Full Text] [Related]
5. Characterization of rat platelet serotonin receptors with tryptamine agonists and the antagonists: ketanserin and SCH 23390.
Killam AL; Cohen ML
Thromb Res; 1991 Nov; 64(3):331-40. PubMed ID: 1805448
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
McBride PA; Mann JJ; Nimchinsky E; Cohen ML
Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
[TBL] [Abstract][Full Text] [Related]
7. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist.
Hara H; Osakabe M; Kitajima A; Tamao Y; Kikumoto R
Thromb Haemost; 1991 Apr; 65(4):415-20. PubMed ID: 2057925
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profiles of R-96544, the active form of a novel 5-HT2A receptor antagonist R-102444.
Ogawa T; Sugidachi A; Tanaka N; Fujimoto K; Asai F
Eur J Pharmacol; 2002 Dec; 457(2-3):107-14. PubMed ID: 12464356
[TBL] [Abstract][Full Text] [Related]
9. A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
Satoh K; Yatomi Y; Ozaki Y
J Thromb Haemost; 2006 Feb; 4(2):479-81. PubMed ID: 16420586
[No Abstract] [Full Text] [Related]
10. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
de Clerck F; David JL; Janssen PA
Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
[TBL] [Abstract][Full Text] [Related]
11. Covalent complexes of albumin with serotonin, ketanserin and lysergic acid antagonize the activity of serotonin in human platelets.
VandenBerg SR; Gonias SL
Life Sci; 1989; 44(23):1777-85. PubMed ID: 2733551
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.
Borawski J; Rydzewski A; Pawlak K; Azzadin A; Buczko W; Mysliwiec M
Thromb Res; 1998 May; 90(4):171-80. PubMed ID: 9692616
[TBL] [Abstract][Full Text] [Related]
13. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
Gleerup G; Persson B; Hedner T; Winther K
Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
[TBL] [Abstract][Full Text] [Related]
14. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
[TBL] [Abstract][Full Text] [Related]
15. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets.
Storck J; Ochs JG; Kirsten R
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):303-8. PubMed ID: 2387654
[TBL] [Abstract][Full Text] [Related]
16. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
De Clerck F; Xhonneux B
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
[TBL] [Abstract][Full Text] [Related]
17. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin.
Nakamura K; Kariyazono H; Moriyama Y; Toyohira H; Kubo H; Yotsumoto G; Taira A; Yamada K
Blood Coagul Fibrinolysis; 1999 Dec; 10(8):513-9. PubMed ID: 10636463
[TBL] [Abstract][Full Text] [Related]
18. Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
Arnout J; Van Russelt M; Deckmyn H; Vermylen J; Fiocchi R; Lijnen P; Amery A
J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S20-2. PubMed ID: 2412049
[TBL] [Abstract][Full Text] [Related]
19. Serotonergic aspects of the response of human platelets to immune-adjuvant muramyl dipeptide.
Polanski M; Karnovsky ML
J Neuroimmunol; 1992 Mar; 37(1-2):149-60. PubMed ID: 1532180
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
Glusa E; Markwardt F
Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
